The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | Optimal diagnostic pathway in mesothelioma
Kevin Blyth, MBChB, MD, FRCP, University of Glasgow, Glasgow, UK, discusses the optimal diagnostic pathway in mesothelioma in the UK, highlighting the importance of accurate actionable information such as detailed histological subtype which can help determine whether immune checkpoint inhibition is suitable, good symptom control, as well as support from nurse specialists. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Rocket Medical and Asbestos Action. Received fees for advisory boards from Rocket Medical, Lily and BMS. Trustee of Mesothelioma UK.
